



Aptus Pharma Pvt. Ltd.

Connecting...Life

NOTICE

Notice is hereby given that 12th Annual General Meeting of members of **APTUS PHARMA PRIVATE LIMITED** will be held on Friday, 30th September, 2022 at 11:00 a.m. at the registered office of the company situated at Shed No. 74-75, Raghuvir Estate, NH – 8, Aslali, Ahmedabad – 382427 to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and adopt the audited financial statement of the Company for the financial year ended on 31st March, 2022 and the Reports of the Board of Directors and the Auditor's thereon.

For and on behalf of Board of Directors
APTUS PHARMA PRIVATE LIMITED

Date: 05/09/2022

Place: Rajkot

TEJASH M. HATHI

Director

DIN: 03151221

NOTE:

1. The member entitled to attend and vote at the meeting may appoint another member as proxy to attend and vote at the meeting on his or her behalf. The instrument appointing the proxy must be deposited at the registered office of company not later than forty eight hours before commencement of meeting.
2. Members and Proxies attending the Meeting should bring the attendance slip duly filled in for attending the Meeting.
3. Corporate Members intending to send their authorized representatives to attend the AGM are requested to send a certified true copy of the Board Resolution/ Authorisation Letter to the Company, authorizing them to attend and vote on their behalf at the AGM.

ENCL.:

1. Attendance Slip
2. Proxy Form (MGT-11)
3. Route Map

Regd. Address: Shed No. 74-75, Raghuvir Estate, NH – 8, Aslali, Ahmedabad, Gujarat – 382427, India.

Contact: 76004 27827, **E-mail:** aptuspharma@rediffmail.com, **Website:** www.aptus-pharma.com

CIN: U24230GJ2010PTC061957, **GSTIN:** 24AA1CA7890D1ZM



Aptus Pharma Pvt. Ltd.[®]

Connecting.....Life

ATTENDANCE SLIP

I certify that I am a registered Member/ Proxy for the registered member of the Company. I hereby record my presence at the Annual general meeting of the Company held **on Friday, 30th September, 2022 at 11:00 a.m.** at the registered office of the company situated at Shed No. 74-75, Raghuvir Estate, NH - 8, Aslali, Ahmedabad - 382427 Name(s) of Shareholder(s):

_____ (Including joint holders if any)

1. Registered Address of the Sole/ First Named Shareholders:

2. Registered Folio No.: _____

3. Number of Equity Share(s) held: _____

4. Name of Proxy if attending for member: _____

(Signature of Member/Proxy)

Note:

1. Only Member/ Proxy holder can attend the meeting.
2. Members/ Proxy holders are requested to bring this Attendance Slip to the Meeting and hand over the same at the entrance duly signed.
3. Bodies Corporate who are members may attend through their authorized representatives appointed under section 113 of the Companies Act, 2013.

Regd. Address: Shed No. 74-75, Raghuvir Estate, NH - 8, Aslali, Ahmedabad, Gujarat - 382427, India.

Contact: 76004 27827, **E-mail:** aptuspharma@rediffmail.com, **Website:** www.aptus-pharma.com

CIN: U24230GJ2010PTC061957, **GSTIN:** 24AAICA7890D1ZM



Aptus Pharma Pvt. Ltd.[®]

Connecting.....Life

**Form No. MGT-11
Proxy form**

[Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration) Rules, 2014]

CIN: **U24230GJ2010PTC061957**

Name of the Company: **APTUS PHARMA PRIVATE LIMITED**

Registered Office: Shed No. 74-75, Raghuvir Estate, NH – 8, Aslali, Ahmedabad – 382427

Name of the member (s):

Registered Address:

E-mail Id:

Folio No:

I/We, being the member (s) of shares of the above named company, hereby appoint

1. Name:

Address:

E-mail Id:

Signature:, or failing him

2. Name:

Address:

E-mail Id:

Signature:, or failing him

3. Name:

Address:

E-mail Id:

Signature:

As my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the Annual general meeting of the company, to be held **on Friday, 30th September, 2022 at 11:00 a.m.** at the registered office of the company

Regd. Address: Shed No. 74-75, Raghuvir Estate, NH – 8, Aslali, Ahmedabad, Gujarat – 382427, India.

Contact: 76004 27827, E-mail: aptuspharma@rediffmail.com, Website: www.aptus-pharma.com

CIN: U24230GJ2010PTC061957, GSTIN: 24AAICA7890D1ZM



Aptus Pharma Pvt. Ltd.[®]

Connecting.....Life

situated at Shed No. 74-75, Raghuvir Estate, NH – 8, Aslali, Ahmedabad – 382427 and at any adjournment thereof in respect of such resolutions as are indicated below:

Resolution No.

1

2

3

Signed this ___ day of _____ 20 ____

Signature of shareholder

Affix
Revenue
Stamp

Signature of Proxy holder(s)

Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting.

Regd. Address: Shed No. 74-75, Raghuvir Estate, NH – 8, Aslali, Ahmedabad, Gujarat – 382427, India.

Contact: 76004 27827, **E-mail:** aptuspharma@rediffmail.com, **Website:** www.aptus-pharma.com


CIN: U24230GJ2010PTC061957, **GSTIN:** 24AAICA7890D1ZM



Aptus Pharma Pvt. Ltd.[®]

Connecting.....Life

Route-map of AGM Venue – Aptus Pharma Private Limited



Regd. Address: Shed No. 74-75, Raghuvir Estate, NH – 8, Aslali, Ahmedabad, Gujarat – 382427, India.
Contact: 76004 27827, **E-mail:** aptuspharma@rediffmail.com, **Website:** www.aptus-pharma.com
CIN: U24230GJ2010PTC061957, **GSTIN:** 24AAICA7890D1ZM

APTUS PHARMA PRIVATE LIMITED

CIN: U24230GJ2010PTC061957

Annual Report for F.Y. 2021-22

Name of Director	Designation
TEJASH M. HATHI (DIN: 03151221)	Director
CHATRABHUJ V. BUTANI (DIN: 03150466)	Director
GHANSHYAM V. PANSURIYA (DIN: 03150975)	Director
KAPILBHAI H. CHANDARANA (DIN: 03151189)	Director

Regd. Address:

Shed No. 74-75, Raghuvir Estate, NH - 8,
Aslali, Ahmedabad, Gujarat - 382427, India.

Contact: 76004 27827

Email: aptuspharma@rediffmail.com

Website: www.aptus-pharma.com



DIRECTORS' REPORT

To,
The Members,

Your Directors have pleasure in presenting their 12th Annual Report on the business and operations of the Company and the accounts for the Financial Year ended **March 31, 2021**.

1. Financial Summary or Highlights:

Particulars	Amount in hundreds	
	F.Y. 2021-22	F.Y. 2020-21
Revenue from operation	10,50,666.30	5,09,579.79
Profit/ (Loss) before interest, depreciation	33,239.42	18247.30
Less: Finance Cost	9,110.10	7595.17
Less: Depreciation	9,506.72	4,290.25
Profit/ (Loss) before tax	14,622.60	6,361.88
Less: Provision for Taxation		
Deferred Tax	(584.72)	(306.57)
Current Tax	5,127.20	2,858.50
Prior Period Adjustment	-	(16.80)
Profit/ (Loss) for the year	10,080.12	3,826.75
Add: Brought forward from the previous year	10,087.00	6,260.25
Less: Transfer to General Reserve	-	-
Balance carried to the Balance Sheet	20,167.12	10,087.00

2. State of Company's Affair:

The year under review was remained very good for the Company. The revenue for the year has been increased to Rs. 10,50,666.30 hundreds as compared to Rs. 5,09,579.79 hundreds in the previous year at the same time expenditure has also increased to Rs. 10,36,050.15 hundreds as compared to Rs. 5,03,264.43 hundreds in the previous year. The company has earned net profit of Rs. 10,080.12 hundreds in the current year as compared to the profit of Rs. 3,826.75 hundreds in the previous year.

3. Web Address of Annual Return :

Annual Return (Form MGT-7A) will be available on the website of Company i.e. www.apтус-pharma.com.



Aptus Pharma Pvt. Ltd.[®]

Connecting.....Life

4. Share Capital:

The paid up equity capital as on 31st March, 2022 was Rs. 30,00,000/-. During the year under review, the Company has issued and allotted 1,75,000 Equity shares of Rs. 10 each at Premium of Rs. 20/- per share to the existing shareholders of the company on right basis.

5. Board of Directors:

During the year under review, there were no changes in directors and key managerial personnel of the company.

6. Board Meetings:

The meeting of the Board of Directors was duly convened and held 5 (Five) times during the year under review. The intervening gap between any two meetings was within the period prescribed under the Companies Act, 2013.

7. Directors' Responsibility Statement:

Pursuant to Section 134 (5) of the Companies Act, 2013, it is hereby confirmed that:

- a) in the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures;
- b) the directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit of the company for the year under review;
- c) the directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- d) the directors have prepared the annual accounts on a going concern basis; and
- e) the directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

8. Statutory Auditors:

As members are aware, pursuant to the provisions of section 139 of the Companies Act, 2013 and the Rules framed there under, M/s. Busa & Associates, Chartered Accountants (FRN: 122574W) was appointed as statutory auditor of the Company for a period of five years at the Annual General Meeting held on 30th September, 2019. M/s. Busa & Associates have confirmed their eligibility to remain continue as the auditor of the Company for their remaining term.



Aptus Pharma Pvt. Ltd.

Connecting.....Life

9. Auditors Report:

The Statutory Auditor has issued Audit Reports with unmodified opinion on the Financial Statements of the Company for the year ended 31st March, 2022. The Notes on the Financials Statement referred to in the Audit Report are self-explanatory and therefore, do not call for any further explanation or comments from the Board of Directors.

10. Reporting of Fraud:

There was no instance of fraud during the year under review, which required the Statutory Auditor to report to the Board under Section 143(12) of the Act and Rules framed there under.

11. Particulars of Contracts or Arrangements with Related Parties:

All contracts/ arrangements/ transactions entered by the Company during the financial year with related parties were in the ordinary course of business and on an arm's length basis. During the year, the Company had not entered into any contract/ arrangement/ transaction with related parties which could be considered material. In view of the above, the requirement of giving particulars of contracts/ arrangements/ transactions made with related parties, in Form AOC-2 are not applicable for the year under review.

12. Material Changes and Commitments:

No material changes and commitments affecting the financial position of the Company occurred between the end of the financial year to which this financial statement relates and the date of this report.

13. Details of Significant and Material Orders Passed by the Regulators, Courts and Tribunals:

No significant and material order has been passed by the regulators, courts, tribunals impacting the going concern status and Company's operations in future.

14. Disclosures under Sexual Harassment of Women at Workplace (Prevention, Prohibition & Redressal) Act, 2013:

The Company is committed to provide a safe and conducive work environment to its employees. During the year under review, no case of sexual harassment was reported.

15. Disclosure about Secretarial Standard:

The Directors have devised proper systems to ensure compliance with the provisions of all applicable Secretarial Standards and that such systems are adequate and operating effectively.



Aptus Pharma Pvt. Ltd.

Connecting.....Life

Acknowledgements:

Your Board places on record sincere gratitude and appreciation for all the employees. The Board conveys its appreciation for its customers, Shareholders, employees, bankers, auditors, end users, business partners and other business constituents during the year under review.

For and on behalf of Board of Directors
APTUS PHARMA PRIVATE LIMITED

Date: 05/09/2022

Place: Rajkot

TEJASH M. HATHI

Director

DIN: 03151221

GHANSHYAM V. PANSURIYA

Director

DIN: 03150975



Independent Auditors' Report

To,
The Members
APTUS PHARMA PRIVATE LIMITED

REPORT ON THE FINANCIAL STATEMENTS

OPINION

We have audited the accompanying financial statements of **M/S. APTUS PHARMA PRIVATE LIMITED**, which comprise the Balance Sheet as at March 31, 2022, the Statement of Profit and Loss for the year ended 31st March, 2022 and notes to the financial statements including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2022, and its profit/loss for the year ended on that date.

BASIS OF OPINION

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

INFORMATION OTHER THAN THE FINANCIAL STATEMENTS AND AUDITOR'S REPORT THEREON

The Company's Board of Directors and Management is responsible for the preparation of the other information. The other information comprises the information obtained at the date of this auditor's report, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.



In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

RESPONSIBILITY OF MANAGEMENT AND THOSE CHARGED WITH GOVERNANCE FOR THE FINANCIAL STATEMENTS

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the company's financial reporting process.

AUDITORS' RESPONSIBILITY FOR THE AUDIT OF FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and



appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. But not for the purpose of expressing an opinion on the effectiveness of the entity's internal controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.



REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENTS

As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, in our opinion and according to the information and explanation given to us, a statement on the matters specified in paragraphs 3 and 4 of the Order is not applicable to the Company.

As required by Section 143(3) of the Act, we report that:

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit.
- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- (c) The Balance Sheet and the Statement of Profit and Loss dealt with by this Report are in agreement with the books of accounts.
- (d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- (e) On the basis of the written representations received from the directors as on 31st March, 2022 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2022 from being appointed as a director in terms of Section 164 (2) of the Act.
- (f) Since the Company's turnover as per last audited financial statements is less than Rs.50 Crores and its borrowings from banks and financial institutions at any time during the year is less than Rs.25 Crores, the Company is exempted from getting an audit opinion with respect to the adequacy of the internal financial controls over financial reporting of the company and the operating effectiveness of such controls vide notification dated June 13, 2017.
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us
 - i. The Company does not have any pending litigations which would impact its financial position
 - ii. The Company does not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.



iv. (a) The management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(b) The management has represented, that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

(c) Based on audit procedures which we considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (a) and (b) contain any material mis-statement.

v. The company has not declared or paid any dividend during the year.

For BUSA & ASSOCIATES
Chartered Accountants



HEMANT BUSA
(Partner)
M. No. 109953
FRN 122574W

Rajkot
September 05, 2022

UDIN : 22109953AXWHUH7435

M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

BALANCE SHEET AS AT 31ST MARCH, 2022.

PARTICULARS	NOTE NO.	AS AT 31.03.2022 AMT. (RS. IN 100)	AS AT 31.03.2021 AMT. (RS. IN 100)
I. EQUITY AND LIABILITIES			
(1) Shareholder's funds			
(a) Share Capital	1	30000.00	12500.00
(b) Reserves & Surplus	2	55167.12	10087.00
(c) Money Received Against Share Warrants	-	NIL	NIL
		85167.12	22587.00
(2) Share Application money pending allotment			
	-	NIL	NIL
		NIL	NIL
(3) Non - Current Liabilities			
(a) Long-term borrowings	3	106676.93	74792.88
(b) Deferred tax liabilities(Net)	-	NIL	NIL
(c) Other Long Term liabilities	-	NIL	NIL
(d) Long-term provisions	-	NIL	NIL
		106676.93	74792.88
(4) Current liabilities			
(a) Short-term borrowings	4	19161.26	58473.22
(b) Trade Payables			
(i) total outstanding dues of micro enterprise and small enterprise; and		NIL	NIL
(ii) total outstanding dues of creditors other than micro enterprises and small enterprises	5	91067.53	55274.19
(c) Other current liabilities	6	92064.19	46549.33
(d) Short-term provisions	7	5855.80	3738.50
		208148.78	164035.24
TOTAL [(1) + (2) + (3)]		399992.83	261415.12
II. ASSETS			
(1) Non-Current Assets			
(a) Property, Plant & Equipment & Intangible Assets			
(i) Property, Plant & Equipment	8	34675.17	12840.35
(ii) Intangible Assets	-	NIL	NIL
(iii) Capital Work- in- Progress	-	NIL	NIL
(iv) Intangible Assets Under Development	-	NIL	NIL
(b) Non-Current Investments	-	NIL	NIL
(c) Deferred Tax Assets (Net)	9	1885.03	1300.31
(d) Long-Term Loans and Advances	-	NIL	NIL
(e) Other Non-Current Assets	10	910.00	910.00
		37470.20	15050.66
(2) Current assets			
(a) Current investment	-	NIL	NIL
(b) Inventories	11	139409.84	78235.93
(c) Trade receivable	12	184958.09	156437.84
(d) Cash and cash equivalents	13	26054.12	7461.24
(e) Short-term loans and advances	14	12100.58	4229.45
(f) Other current assets	-	NIL	NIL
		362522.63	246364.46
Total [(1) +(2)]		399992.83	261415.12

The accompanying notes form an integral part of the accounts - 22

As per our report of even date

For BUSA & ASSOCIATES
Chartered Accountants

HEMANT BUSA
(Partner)
M.No. 109953
FRN 122574W



For APTUS PHARMA PRIVATE LIMITED

Director
Tejas
Hathi
DIN:3151221

Director
Ghanshyam
Pansuriya
DIN:3150975

UDIN: 22109953AXWHUH7435

Rajkot

September 05, 2022

M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

MANUFACTURING, PROFIT & LOSS ACCOUNT FOR THE PERIOD ENDED 31ST MARCH, 2022.

PARTICULARS	NOTE NO.	CURRENT YEAR AMT. (RS. IN 100)	PREVIOUS YEAR AMT. (RS. IN 100)
INCOME			
I. Revenue from operation	15	1050666.30	509579.79
II. Other income	16	6.45	46.52
III. Total income(I+II)		1050672.75	509626.31
IV. Expenses:			
(a) Cost of materials consumed	-	NIL	NIL
(b) Purchase of stock- in- Trade	17	444223.92	207273.82
(c) Changes in inventories of finished goods work-in-progress and Stock-in-Trade	18	(61173.91)	(38021.87)
(d) Employee benefit expense	19	87733.55	41185.00
(e) Finance costs	20	9110.10	7595.17
(f) Depreciation and amortization expense	8	9506.72	4290.25
(g) Other expenses	21	546649.77	280942.06
Total Expenses [(a) to (g)]		1036050.15	503264.43
V. Profit before exceptional and extraordinary items and tax (III-IV)		14622.60	6361.88
VI. Exceptional items		NIL	NIL
VII. Profit before extraordinary items and tax (V-VI)		14622.60	6361.88
VIII. Extraordinary items		NIL	NIL
IX. Profit before tax (VII-VIII)		14622.60	6361.88
X. Tax expense:			
(1) Current tax		5127.20	2858.50
(2) Deferred tax		(584.72)	(306.57)
(3) Prior Period Taxation Adjustment		0.00	(16.80)
XI. Profit (Loss) for the period from continuing operation (VII-VIII)		10080.12	3826.75
XII. Profit / (Loss) for the period from discontinuing operation		NIL	NIL
XIII. Tax expense of discontinuing operations		NIL	NIL
XIV. Profit/ (Loss) for the period from discontinuing operation (after tax) (XII-XIII)		NIL	NIL
XV. Profit (Loss) for the period (XI+XIV)		10080.12	3826.75
XVI. Earning per Equity share:			
(1) Basic (in Rs.)		6.90	3.06
(2) Diluted (in Rs.)		6.90	3.06

The accompanying notes form an integral part of the accounts - 22

As per our report of even date


For BUSA & ASSOCIATES
Chartered Accountants

HEMANT BUSA
(Partner)
M.No. 109953
FRN 122574W


UDIN: 22109953AXWHUH7435

Rajkot
September 05, 2022

For APTUS PHARMA PRIVATE LIMITED


Director
Tejas
Hathi

DIN:3151221


Director
Ghanshyam
Pansuriya
DIN:3150975

17/12/2022

M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT
NOTES TO THE BALANCE SHEET AS AT 31ST MARCH, 2022.

PARTICULARS	CURRENT YEAR		PREVIOUS YEAR	
	NUMBER OF SHARES	AMOUNT (IN RS. 100)	NUMBER OF SHARES	AMOUNT (IN RS. 100)
NOTE "1"				
SHARE CAPITAL				
Authorized				
Equity Shares of Rs. 10 Each With Voting Rights	300000	30000.00	300000	30000.00
	<u>300000</u>	<u>30000.00</u>	<u>300000</u>	<u>30000.00</u>
Issued				
Equity Shares of Rs. 10 Each With Voting Rights	300000	30000.00	125000	12500.00
	<u>300000</u>	<u>30000.00</u>	<u>125000</u>	<u>12500.00</u>
Subscribed and Fully Paid up				
Equity Shares of Rs. 10 Each With Voting Rights	300000	30000.00	125000	12500.00
	<u>300000</u>	<u>30000.00</u>	<u>125000</u>	<u>12500.00</u>

PARTICULARS	CURRENT	PREVIOUS
	YEAR AMT. (IN RS. 100)	YEAR AMT. (IN RS. 100)
NOTE "2"		
RESERVES & SURPLUS		
1 Share Premium	35000.00	NIL
	<u>"A" 35000.00</u>	<u>NIL</u>
2 Surplus/(Deficit) in Statement of Profit and Loss		
Opening balance	10087.00	6260.25
Add: Profit / (Loss) for the year	10080.12	3826.75
	<u>"B" 20167.12</u>	<u>10087.00</u>
TOTAL (A+B)	<u>55167.12</u>	<u>10087.00</u>

NOTE "3"
LONG TERM BORROWINGS

TERM LOANS

1 From banks/financial institutions

Secured	1872.23	5401.09
Unsecured	17034.73	25121.82

2 From other parties

Secured	NIL	NIL
Unsecured	87769.97	44269.97
	<u>106676.93</u>	<u>74792.88</u>



M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

NOTES TO THE BALANCE SHEET AS AT 31ST MARCH, 2022.

PARTICULARS	CURRENT YEAR AMT. (IN RS. 100)	PREVIOUS YEAR AMT. (IN RS. 100)
-------------	--------------------------------------	---------------------------------------

NOTE "4"

SHORT TERM BORROWINGS

LOAN REPAYABLE ON DEMAND

1 From banks

Secured

NIL

31845.07

2 From other parties

Unsecured

NIL

NIL

"A"

NIL

31845.07

CURRENT MATURITIES OF LONG TERM BORROWINGS

From Banks

1 ICICI Bank -Car Loan (Agreement No.

897.12

772.68

2 Central Bank of India (Agreement. No. 3812062248)

180.88

2500.00

3 Central Bank of India (Agreement. No. 3832008015)

1980.00

1950.00

4 HDFC Bank (Agreement No.

5792.92

4579.36

From Financial Institutions

1 Digikredit Finance Pvt. Ltd.

4486.93

11931.62

2 Bajaj Finance Ltd. (Agreement No.

5823.41

4894.49

"B"

19161.26

26628.15

TOTAL (A+B)

19161.26

58473.22

NOTE "5"

TRADE PAYABLES

TRADE PAYABLES DUE FOR PAYMENT

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i) MSME	0.00	0.00	-	-	0.00
(ii) Others	90855.64	211.89	-	-	91067.53
(iii) Disputed Dues - MSME	-	-	-	-	-
(iv) Disputed Dues - others	-	-	-	-	-
TOTAL	90855.64	211.89	-	-	91067.53
(i) MSME	0.00	-	-	-	0.00
(ii) Others	55274.19	-	-	-	55274.19
(iii) Disputed Dues - MSME	-	-	-	-	-
(iv) Disputed Dues - others	-	-	-	-	-
PREVIOUS YEAR	55274.19	-	-	-	55274.19



M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

NOTES TO THE BALANCE SHEET AS AT 31ST MARCH, 2022.

PARTICULARS	CURRENT YEAR AMT. (IN RS. 100)	PREVIOUS YEAR AMT. (IN RS. 100)
-------------	--------------------------------------	---------------------------------------

NOTE "6"

OTHER CURRENT LIABILITIES

1 Statutory Liabilities	3194.72	8789.82
2 Advance Received from Customers	2810.58	8025.76
3 Other Payables	86058.89	29733.75
	92064.19	46549.33

NOTE "7"

SHORT TERM PROVISIONS

1 Provision for employee benefits	NIL	NIL
2 Provision for Taxation	5075.80	2858.50
3 Provision - Others	780.00	880.00
	5855.80	3738.50

NOTE "8" PROPERTY, PLANT & EQUIPMENT

SR. NO.	NAME OF THE ASSETS	RATE (%)	GROSS BLOCK			ACCUMULATED DEPRECIATION			(AMT. IN RS. 100)			
			BALANCE AS AT 31.03.21	ADDITION DU. THE YEAR	DELETION DU. THE YEAR	BALANCE AS AT 31.03.22	BALANCE AS AT 31.03.21	ADDITION DU. THE YEAR	DELETION DU. THE YEAR	BALANCE AS AT 31.03.22	CLOSING BALANCE 31.03.22	CLOSING BALANCE 31.03.21
Own Assets:												
1	Air Conditioner	25.89%	5441.10	1180.35	0.00	6621.45	2211.78	1025.11	0.00	3256.89	3384.56	3229.32
2	Computer	63.16%	5912.14	8825.71	0.00	14737.85	2925.46	4699.77	0.00	7625.23	7112.62	2986.66
3	C.C. TV Camera	25.89%	358.77	0.00	0.00	358.77	131.11	58.94	0.00	190.05	168.72	227.66
4	Furniture & Fixture	25.89%	1236.23	11562.52	0.00	13198.75	1049.32	1048.05	0.00	2097.37	11101.58	186.91
5	Mobile Phone	25.89%	3765.49	7069.83	0.00	10835.32	1249.03	1447.01	0.00	2696.04	8139.28	2516.46
6	Fan	25.89%	81.00	0.00	0.00	81.00	66.68	3.71	0.00	70.39	10.61	14.32
7	Car Ignia	31.23%	4670.71	0.00	0.00	4670.71	3038.38	509.78	0.00	3548.16	1122.55	1632.23
8	Refrigerator	25.89%	599.16	600.00	0.00	1199.16	105.26	195.65	0.00	301.03	897.23	493.88
9	Software	63.16%	196.00	0.00	0.00	196.00	138.41	36.37	0.00	174.78	21.22	57.59
10	Fire Extinguisher	25.89%	56.00	0.00	0.00	56.00	4.81	13.25	0.00	18.00	37.94	51.19
11	Generator	25.89%	1737.29	0.00	0.00	1737.29	293.28	373.85	0.00	667.13	1070.16	1444.01
12	Inverter	25.89%	0.00	1703.13	0.00	1703.13	0.00	94.23	0.00	94.23	1608.90	0.00
			24053.89	31341.54	0.00	55395.43	11213.94	9306.72	0.00	20720.38	34475.17	12840.32
	PREVIOUS YEAR		16347.26	7706.43	0.00	24053.89	6923.29	4290.25	0.00	11213.54	12840.32	9423.97



M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

NOTES TO THE BALANCE SHEET AS AT 31ST MARCH, 2022.

PARTICULARS	CURRENT YEAR AMT. (IN RS. 100)	PREVIOUS YEAR AMT. (IN RS. 100)
-------------	--------------------------------------	---------------------------------------

NOTE "9"

DEFERRED TAX ASSETS

Timing Difference due to depreciation

Opening Balance

Add/(Less) : Addition/Deletion during the year

1300.31

993.74

584.72

306.57

1885.03

1300.31

NOTE "10"

OTHER NON CURRENT ASSETS

1 Deposit

1 Packing Material Deposit

2 Rent Deposit- Hina Bhalodiya

3 Rent Deposit- Kanchanben Bhalodiya

400.00

400.00

200.00

200.00

310.00

310.00

910.00

910.00

NOTE "11"

INVENTORIES

A Finished Goods

1 Finished Goods

139409.84

78235.93

139409.84

78235.93

"A"

NOTE "12"

TRADE RECEIVABLES

TRADE RECEIVABLES DUE FOR PAYMENT							
Particulars	Outstanding for following periods from due date of payment						Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years		
(i) Considered good secured	183654.87	598.16	705.06	0.00	0.00		184958.09
(ii) Considered doubtful	-	-	-	-	-	-	-
(iii) Considered Good	-	-	-	-	-	-	-
(iv) considered doubtful	-	-	-	-	-	-	-
TOTAL	183654.87	598.16	705.06	0.00	0.00		184958.09
(i) Considered good secured	149601.54	6836.3	0	0	0		156437.84
(ii) Considered doubtful	-	-	-	-	-	-	-
(iii) Considered Good	-	-	-	-	-	-	-
(iv) considered doubtful	-	-	-	-	-	-	-
PREVIOUS YEAR	149601.54	6836.3	0	0	0		156437.84



M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

NOTES TO THE BALANCE SHEET AS AT 31ST MARCH, 2022.

<u>PARTICULARS</u>	<u>CURRENT YEAR AMT. (IN RS. 100)</u>	<u>PREVIOUS YEAR AMT. (IN RS. 100)</u>
NOTE "13"		
CASH & CASH EQUIVALENTS		
1 Cash in Hand	20959.74	6461.00
2 Bank Balance With-		
- Central Bank Of India (Current A/c No. 3194905788)	2.42	1000.24
- HDFC Bank Ltd. (Current A/c 59209879162647)	500.00	NIL
- Central Bank Of India (OD A/c No. 3498339851)	4591.96	NIL
	<u>26054.12</u>	<u>7461.24</u>
NOTE "14"		
SHORT TERM LOANS & ADVANCES		
1 Prepaid Expenses	1978.83	934.74
2 Balance With Government Authorities	6458.45	578.54
3 Other Loans & Advances	3663.30	2716.17
	<u>12100.58</u>	<u>4229.45</u>



M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

**NOTES FORMING PARTS TO THE MANUFACTURING, PROFIT AND LOSS
ACCOUNT FOR THE PERIOD ENDED 31ST MARCH, 2022.**

PARTICULARS	CURRENT YEAR AMT. (IN RS. 100)	PREVIOUS YEAR AMT. (IN RS. 100)
NOTE "15"		
REVENUE FROM OPERATIONS		
Sales - GST	1115756.77	526545.51
Less : Sales Return /Credit Note	65090.47	16965.72
	1050666.30	509579.79
NOTE "16"		
OTHER INCOME		
INDIRECT INCOME		
1 Kasar	6.45	46.52
TOTAL	6.45	46.52
NOTE "17"		
PURCHASE OF STOCK-IN-TRADE		
1 Drugs & Medicines Purchases	457785.61	221800
Less: Purchase Return	13561.69	14526.3
	444223.92	207273.82
NOTE "18"		
CHANGES IN INVENTORIES		
Finished Goods		
Closing Stock	139409.84	78235.93
Less: Opening Stock	78235.93	40214.06
	(61173.91)	(38021.87)
NOTE "19"		
EMPLOYEE BENEFIT EXPENSES		
1 Office & Sales Staff Bonus	1480.00	660.00
2 Office & Sales Staff Salary	80756.56	37927.09
3 Office Employee Insurance Premium	NIL	677.75
4 Provident Fund	3190.12	1920.16
5 Staff Welfare Expenses	2306.87	NIL
TOTAL	87733.55	41185.00



M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

**NOTES FORMING PARTS TO THE MANUFACTURING, PROFIT AND LOSS
ACCOUNT FOR THE PERIOD ENDED 31ST MARCH, 2022.**

PARTICULARS	CURRENT YEAR AMT. (IN RS. 100)	PREVIOUS YEAR AMT. (IN RS. 100)
-------------	--------------------------------------	---------------------------------------

NOTE "20"

FINANCIAL EXPENSES

1 Bank Charges	418.63	270.57
2 Bank CC Interest	722.34	2028.16
3 Bank Loan Processing Charges	294.47	1607.06
4 Interest On Car Loan	124.44	193.14
5 Interest On Term Loan- CBI	469.14	553.72
6 Interest On Term Loan- Bajaj Finance	1918.25	1135.67
7 Interest On Term Loan- Digicredit	2644.6	325.05
8 Interest On Term Loan- India Bulls	NIL	55.39
9 Interest On Term Loan- HDFC	2446.94	1257.93
10 Interest On Late Payment of Profession Tax	59.06	5.47
11 Interest On Late Payment of TDS	12.23	163.01
TOTAL	9110.10	7595.17

NOTE "21"

OTHER EXPENSES

(A) DIRECT EXPENSES

1 Cylinder Charges	897.00	1089.60
2 Discount Expenses	115053.07	77943.19
3 Electricity Expenses	98.11	221.02
4 Freight Expenses	1369.55	849.85
5 Godown Rent Expenses	100.00	1200.00
6 INS Charges	3.78	13.16
7 Inventory Charges	54.63	31.50
8 Packing & Forwarding Expenses	340.69	321.32
9 Product Designing Expenses	386.00	362.00
10 Product Development Charges	30.00	150.00
11 Product Expiry Expenses	302.12	966.40
12 Product Permission Charges	7795.50	4221.30
13 Product Testing Expenses	6441.50	1644.50
14 Rate Difference	48231.09	3316.66
15 Transportation Expenses - Inward	4110.47	2181.01
"A"	185213.51	94511.51

(B) ADMINISTRATIVE AND SELLING EXPENSES

1 Accounting Salary	2640.00	2640.00
2 Advertisement Expenses	3932.80	3050.00
3 Audit Fees	290.00	250.00
4 Bad Debts	1265.37	159.75
5 Commission Expenses	54971.12	31141.85
6 Computer & Printer Repairing Expenses	1279.60	400.71
7 Conference & Meeting Expenses	16190.03	8702.85
8 Conveyance Expenses	1440.00	2040.00
9 Directors Remuneration	15668.75	16413.00
10 Discount Expense on Payments	13627.90	6637.71
11 Donation	3330.00	250.00
12 Driver Salary Expenses	2280.00	2280.00

TOTAL C/F

116915.57

73965.87



M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

**NOTES FORMING PARTS TO THE MANUFACTURING, PROFIT AND LOSS
ACCOUNT FOR THE PERIOD ENDED 31ST MARCH, 2022.**

PARTICULARS	CURRENT YEAR AMT. (IN RS. 100)	PREVIOUS YEAR AMT. (IN RS. 100)
NOTE "21"		
OTHER EXPENSES		
(B) ADMINISTRATIVE AND SELLING EXPENSES (Contd...)		
	TOTAL B/F	116915.57
		73965.87
13 GST Expenses	NIL	4.20
14 GST Return Late Filing Fees	153.50	357.50
15 Insurance Expenses	1929.63	232.65
16 ISO Certification Fees	NIL	200.00
17 Legal Fees	2830.00	2255.00
18 Membership Fees	47.52	362.58
19 Miscellaneous Expenses	300.20	30.00
20 Office Expenses	9614.19	2463.05
21 Office Rent Expenses	3996.00	2190.00
22 Packing Material Expenses	1187.88	940.26
23 Postage & Courier Expenses	3962.47	1057.01
24 Profession Tax	25.2	24.00
25 Professional Fees	100	30.00
26 Repairs & Maintenance Expense (Electric)	428.93	NIL
27 ROC Fees	31	20.00
28 Sales Promotion Expenses	168158.82	78352.27
29 Software Expenses	182.2	91.80
30 Stationery & Printing Expenses	15366.74	4031.41
31 Telephone Expenses	156.77	153.86
32 Tours & Travelling Expenses	NIL	61.20
33 Transportation Expenses - Outward	1922.45	2204.11
34 Travelling Expenses (Field Staff)	32356.51	16675.75
35 Vehicle Insurance Premium	NIL	19.00
36 Vehicle Petrol & Repairing Expenses	1770.68	709.03
	"B"	361436.26
		186430.55
	TOTAL (A+B)	546649.77
		280942.06



APTUS PHARMA PRIVATE LIMITED: RAJKOT

NOTE- 22

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES AND NOTES FORMING PART TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31ST MARCH, 2022.

a. SIGNIFICANT ACCOUNTING POLICIES

1. ACCOUNTING METHOD

The Company recognizes all income and expenditure having a material bearing on the financial statements on accrual basis. The financial statements are prepared in accordance with Accounting Standards issued by the Institute of Chartered Accountants of India and the provisions of the Companies Act, 2013 as adopted consistently by the company.

2. ACCOUNTING CONVENTION

The financial statements are prepared under the historical cost convention ignoring changes, if any, in the purchasing power of money.

3. PROPERTY, PLANT & EQUIPMENT

Property, Plant & Equipment are stated at the cost of acquisition. The cost of asset includes other direct /indirect and incidental cost incurred to bring them into their present location. The Company has not revalued its property, plant and equipment (including right of use asset) during the year.

4. PRIOR PERIOD, EXTRA ORDINARY AND EXCEPTIONAL ITEMS

- a) Items of Incomes or Expenses which aroused in the current year but the conditions, events or evidences for those transactions relates to one or more prior periods are separately disclosed in the Financial Statements.
- b) The items of Incomes or Expenditure which does not relates to ordinary business activities are classified as Extra ordinary items in the Financial Statements.
- c) Income or Expenditures which relates to ordinary business activities but are exceptionally high or low as compared to one or more comparatives are classified as Exceptional items.
- d) There is no change in any accounting policy or accounting estimates or the enterprise which materially affect the Financial Statements of the enterprise.

There are no prior period, extra ordinary and exceptional items during the year under audit.



APTUS PHARMA PRIVATE LIMITED: RAJKOT

NOTE- 22 (Contd...)

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES AND NOTES FORMING PART TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31ST MARCH, 2022.

5. DEPRECIATION

Depreciation on Property, Plant & Equipment is provided by complying the provisions contained in schedule- II of the Companies Act, 2013.

- a) Depreciation is provided using Written Down Value Method, after retaining residual value at the rate of 5% of the cost, over the useful lives of the assets prescribed in schedule-II of the Act.
- b) In case of assets purchased during the year, Depreciation is provided on prorata basis on the basis of useful lives prescribed in Schedule-II.

6. BORROWING COST

Borrowing costs that are attributable to the acquisition or construction of qualifying assets are capitalized as part of the cost of such asset. All other borrowing costs are charged to the revenue. There are no borrowing costs capitalized during the year under audit.

7. REVENUE RECOGNITION

The revenues are recognized as and when accrued and when it is reasonably certain that the ultimate collection will be made in respect of principal activity of business. In other cases revenue is recognized when right to receive income is established.

8. FOREIGN CURRENCY TRANSACTIONS

There are no transactions in foreign currency entered into by the company during the year under consideration.

9. GOVERNMENT GRANTS/INCENTIVES

Company has not received any Government Grants during the year under consideration.

10. EMPLOYEE BENEFITS

Provident fund: Contribution as required under the statute/rules is made to the Government Provident Fund.



APTUS PHARMA PRIVATE LIMITED: RAJKOT

NOTE- 22 (Contd...)

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES AND NOTES FORMING PART TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31ST MARCH, 2022.

11. EARNING PER SHARE

As per the Accounting Standard issued by ICAI the basic earning/(loss) are calculated by dividing the Net Profit/Loss after Taxation for the year, which is attributable to the equity share holders, is Rs. 6.90. The number of shares used in computing the basic earnings per share is the weighted average number of shares outstanding during the year.

12. TAXES ON INCOME

- a) Provision for income tax is made on the basis of taxable income for the year at current rates.
 - b) Tax expense comprises of current Tax, Fringe Benefit Tax and Deferred Tax at the applicable enacted or substantively enacted rates.
- Current tax represents the amount of Income tax payable/recoverable in respect of the taxable income/loss for the reporting period.
 - Deferred tax represents the effect of timing difference between taxable income and accounting income for the reporting period that originates in one period and are capable of reversal in one or more subsequent periods. The deferred tax asset is recognized and carried forward only to the extent that there is a reasonable certainty the asset will be realized in future. However, where there is unabsorbed depreciation or carried forward loss under taxation laws, deferred tax assets are recognized only if there is virtual certainty of realization of assets.

13. SEGMENT REPORTING

As the company's business activities will fall within a single primary business segment, the disclosure requirements of Accounting Standard 17 "Segment Reporting" issued by the ICAI are not applicable.

14. PROVISIONS, CONTINGENT LIABILITIES AND CONTINGENT ASSETS

A provision is recognized when an enterprise has present obligations as a result of past event and is probable that an outflow of resources will be required to settle the obligation in respect of which reliable estimates can be made.

Provisions are not discounted to their present value and are determined based on management estimates required to settle the obligations at the balance sheet date. These are reviewed at the balance sheet date and adjusted to reflect the current management estimates.



APTUS PHARMA PRIVATE LIMITED: RAJKOT

NOTE-22 (Contd..)

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES AND NOTES FORMING PART TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31ST MARCH, 2022.

15. IMPAIRMENT OF ASSETS

The Company assess at Balance Sheet date whether there is any indication that an asset may be impaired. If any such indication exists, the Company estimates the recoverable amount of the assets. If such recoverable amount of the asset or the recoverable amount of the cash generating unit to which the asset belongs is less than its carrying amount, the carrying amount is reduced to its recoverable amount. The reduction is treated as an impairment loss and is recognized in the profit and loss account. If at the balance sheet date there is an indication that if a previously assessed impairment loss no longer exists, the recoverable amount is reassessed and the asset is reflected at the recoverable amount.

b. NOTES ON ACCOUNTS

1. LONG TERM BORROWINGS

- 1) The Company has used the borrowings from banks and financial institutions for the specific purpose for which it was taken as at the reporting date.
- 2) The Company does not have any charges or satisfaction which is yet to be registered with Registrar of Companies (ROC) beyond the statutory period except Car Loan from ICICI Bank.

2. SHORT TERM BORROWINGS

- 1) The Company has not been sanctioned working capital limits in excess of five crore rupees in aggregate, from banks or financial institutions on the basis of security of current assets at any point of time during the year.
- 2) The Company is not declared as wilful defaulter by any bank or financial institution or other lenders.

3. INVENTORIES

- 1) Inventories are taken, valued and certified by the Management.
- 2) Inventories are valued at cost or net realizable value whichever is lower following FIFO Method.
- 3) The Company has physically verified the inventories at reasonable intervals and there are no discrepancies of 10% or more in the aggregate for each class of inventory noticed during such verification.

4. TRADE RECEIVABLES

- 1) Trade receivables are neither due from directors or other officers of the Company either severally or jointly with any other person, nor any trade or other receivables are due from firms or private companies respectively in which any director is a partner, a director or a member.
- 2) There are no receivables due from the related parties.
- 3) Refer Note No. 12 for the ageing schedule of Trade Receivables



APTUS PHARMA PRIVATE LIMITED: RAJKOT

NOTE-22 (Contd..)

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES AND NOTES FORMING PART TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31ST MARCH, 2022.

5. CURRENT ASSETS, LOANS AND ADVANCES AND LIABILITIES

- 1) In the opinion of the Board of Directors, the value on realization of current assets, loans and advances, if realized in the ordinary course of the business, shall not be less than the amount, which is stated, in the current year Balance sheet. The provision for all known liabilities is reasonable and not in excess of the amount considered reasonably necessary.
- 2) The Company has not granted any loan or advance in the nature of loan to promoters, directors, KMPs and other related parties that are repayable on demand or without specifying any terms or period of repayment.

6. DISCLOSURE REQUIREMENT FOR SUNDRY CREDITORS COVERED UNDER MSME ACT, 2006

As informed by the management, the company has circulated confirmation for the identification of suppliers registered under the Micro, Small and Medium Enterprises Development Act, 2006. *The company however has not received any confirmation from suppliers regarding their status under the Micro, Small and Medium Enterprises Development Act, 2006 and hence disclosures, relating to amounts unpaid, if any, as at the year end together with interest paid/payable as required under the said Act have not been given in our financial statement.*

7. DISCLOSURE UNDER SECTION 73 OF COMPANIES ACT, 2013

In view of provisions of section 73 of the Companies Act, 2013 read with Companies (Acceptance of Deposits) Rules, 2014 and General Circular No. 05/2015 dated 30th March, 2015 issued by Ministry of Corporate Affairs, Government of India, disclosures relating to unsecured loans and deposits accepted are given as under.

The company has not accepted unsecured loans from "persons other than directors or their relatives" which is considered as deposits as per the provisions of companies Act, 2013.

8. PARTICULARS OF RAW MATERIALS, WORK IN PROGRESS, OTHER MATERIALS AND FINISHED GOODS UNDER BROAD HEADS

As taken, valued and certified by management, in view of disclosure requirements of revised schedule VI regarding disclosure of Raw Materials, Work in Process and Finished Goods under broad heads, the items wise details in respect of each of item is not presented as the same is not made available by the management.



APTUS PHARMA PRIVATE LIMITED: RAJKOT

NOTE-22 (Contd..)

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES AND NOTES FORMING PART TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31ST MARCH, 2022.

9. DEFERRED TAX ASSETS/LIABILITIES

Provision for current tax is made after taking into consideration benefits admissible under the provisions of income tax Act, 1961. Deferred tax resulting from timing difference between book and taxation profit is accounted for using the tax rates and laws that have been enacted or substantively enacted on the date of balance sheet. The deferred tax asset and liabilities are recognized and carried forward only to the extent that there is reasonable certainty that the assets will be realized in future. Break up of Net Deferred Tax Liability/(Asset) into major components is given below:

(Amt. in Rs. '00)				
Sr. No.	Particulars	Deferred tax (asset)/Liability as on 01.04.2021	Add/(Less) Current Year	Deferred tax (asset)/Liability as on 31.03.2022
1.	Depreciation (Timing Difference)	(1300.31)	584.72	(1885.03)
2.	Disallowance U/s	-	-	-
	TOTAL	(1300.31)	584.72	(1885.03)

10. DIRECTOR'S REMUNERATION

Amount of Rs. 15,66,8.75 hundreds has been given to Directors by way of Remuneration during the financial year covered under audit.

11. AUDITOR'S REMUNERATION

Auditor's Remuneration has been provided as below:

(Amt. in Rs. '00)			
Sr. No.	Particulars	Remuneration	
		Current Year	Previous Year
1.	Statutory Audit Fees	185.00	185.00
2.	Tax Audit Fees	65.00	65.00
	Total	250.00	250.00

12. FOREIGN EXCHANGE EARNING AND OUTGO

The company has not earned and spent major foreign exchange during the financial year covered under audit.



APTUS PHARMA PRIVATE LIMITED: RAJKOT

NOTE-22 (Contd..)

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES AND NOTES FORMING PART TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31ST MARCH, 2022.

13. RELATED PARTY TRANSACTIONS

As per Accounting Standard 18, disclosure of transaction with related parties as defined in Accounting Standard are given below:

Sr. No.	Name of Related Parties	Relationship	Nature of Transaction	Amount (in Rs. 00)
1	Tejasbhai M. Hathi	Key Managerial Personnel	Director's Remuneration	8400.00
2	Ghanshyambhai Pansuriya	Key Managerial Personnel	Director's Remuneration	4400.00
3	Kapilbhai Chandarana	Key Managerial Personnel	Director's Remuneration	2868.75
4	Yeshaben G. Pansuriya	Key Managerial Personnel's Relative	Salary	2640.00
5	Grishmaben K. Chandarana	Key Managerial Personnel's Relative	Salary	2640.00
5	Tejasbhai M. Hathi	Key Managerial Personnel	Unsecured Loan taken of Rs. 162500.00 and repaid during the year of Rs.119000.00 O/S as on 31.03.2022 Rs. 55756.53	

14. CONFIRMATION

Balance of Bank and Cash, Loans & Advances, Sundry Debtors & Sundry Creditors are subject to confirmation

15. GRATUITY

Company has not made the provision for gratuity in the books of accounts.

16. PREVIOUS YEAR'S FIGURES

Previous year's figures have been regrouped/rearranged wherever necessary to make them comparable with the figures of the current year.



APTUS PHARMA PRIVATE LIMITED: RAJKOT

NOTE-22 (Contd..)

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES AND NOTES FORMING PART TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31ST MARCH, 2022.


17. ROUNDING OFF OF FIGURES

Figures have been rounded off to hundreds upto two decimals.

18. OPENING BALANCES

Opening Balances are taken from the audited balance sheet of the last year.


**For BUSA & ASSOCIATES
Chartered Accountants**


**HEMANT BUSA
(Partner)
M.No. 109953
FRN: 122574W**



FOR APTUS PHARMA PRIVATE LIMITED


**(DIRECTOR)
Tejas
Hathi
DIN:3151221**


**(DIRECTOR)
Ghanshyam
Pansuriya
DIN:3150975**

**Rajkot
September 05, 2022**

APTUS PHARMA PRIVATE LIMITED: RAJKOT

Additional regulatory and other information as required by the Schedule III to the Companies Act 2013

1) Proceedings under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder

There are no proceedings initiated or are pending against the company for holding any Benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder

2) Relationship with Struck off Companies

The Company did not have any transactions with Companies struck off under Section 248 of Companies Act, 2013 or Section 560 of Companies Act, 1956 considering the information available with the Company.

3) Compliance with number of layers of companies

The Company do not have any parent company and accordingly, compliance with the number of layers prescribed under clause (87) of section 2 of the Act read with Companies (Restriction on number of Layers) Rules, 2017 is not applicable for the year under consideration.

4) Accounting Ratios

(Amt. in Rs. '00)

PARTICULARS	NUMERATOR	DENOMINATOR	AS AT	AS AT	VARIANCE
			31 ST	31 ST	
			MARCH	MARCH	
			2022	2021	
(a) Current Ratio,	362522.63	208148.78	1.74	1.50	15.96%
(b) Debt-Equity Ratio,	314825.71	85167.12	3.70	10.57	-65.04%
(c) Debt Service Coverage Ratio,	33168.13	28200.07	1.18	0.40	190.49%
(d) Return on Equity Ratio,	10080.12	30000.00	33.60%	30.61%	9.76%
(e) Inventory turnover ratio,	NA	NA	NA	NA	NA
(f) Trade Receivables turnover ratio,	1050666.30	170697.97	6.16	3.66	68.05%
(g) Trade payables turnover ratio,	444223.92	73170.86	6.07	4.09	48.33%
(h) Net capital turnover ratio,	1050666.30	30000.00	35.02	40.77	-14.09%
(i) Net profit ratio,	10080.12	1050666.30	0.96%	0.75%	27.76%
(j) Return on Capital employed,	22297.26	191844.05	11.62%	10.32%	12.60%
(k) Return on investment,	NA	NA	NA	NA	NA



Reasons for Variances :

- a.) Debt-Equity Ratio : Variance in ratio is mainly due to increase in total liabilities of the company owing to overall increase in business of the company.
- b.) Debt Service Coverage Ratio : Variance in ratio is due to increase in profits of the company.
- c.) Trade Receivables Turnover Ratio : Variance in ratio is mainly due to increase in Sales & corresponding Trade Receivables of the company.
- d.) Trade Payable Turnover Ratio : Variance in ratio is mainly due to increase in Purchases & corresponding Trade Payables of the company.
- e.) Net Profit Ratio : Variance in ratio is mainly due to increase in profitability of the company owing to increased business.

5) Scheme of arrangements

There are no Scheme of Arrangements approved by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013 during the year.

6) Advance or loan or investment to intermediaries and receipt of funds from intermediaries

The company has not advanced or loaned or invested funds (either borrowed funds or share premium or any other sources or kind of funds) to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding (whether recorded in writing or otherwise) that the Intermediary shall (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or (ii) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.

The company has also not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the company shall (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or (ii) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

7) Undisclosed Income

The Company do not have any transaction which are not recorded in the books of accounts that has been surrendered or disclosed as income in the tax assessments under the Income Tax Act, 1961 during any of the years.

8) Details of Crypto Currency or Virtual Currency

The Company did not trade or invest in Crypto Currency or virtual currency during the financial year. Hence, disclosures relating to it are not applicable.



9) Reclassification of previous year figures upon complying with Schedule III Amendments

The Company is required to comply with the amendments in Schedule III of Companies Act, 2013 notified on 24-03-2021, with effect from 01-04-2021. Accordingly the Company has complied with the disclosure and presentation requirements as per the aforesaid amendments and reclassified the following items in the previous years, to conform to current year classification.

Nature of reclassification	Amount of each item reclassified (in Rs. '00)		Reason for reclassification
	As at 31 st March 2022	As at 31 st March 2021	
Hitherto, Current maturities of Long term borrowings was included in Other Current Financial Liabilities. As per the requirement under amendments to Schedule III, the same has been presented under 'Short Term Borrowings' as a separate line and previous year figure has been reclassified	19161.26	26628.15	As required by Amendments to Schedule III to the Companies Act

For BUSA & ASSOCIATES
Chartered Accountants

HEMANT BUSA
(Partner)
M.No. 109953
FRN: 122574W



FOR APTUS PHARMA PRIVATE LIMITED

Tejas Hathi
(DIRECTOR)
DIN:3151221

Ghanshyam Pansuriya
(DIRECTOR)
DIN:3150975

Rajkot
September 05, 2022

M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT**SUB NOTE TO NOTE "1"
SHARE CAPITAL**

(i) Reconciliation of the number of shares and amount outstanding at the beginning and at the end of the reporting period:

Particulars	(AMT. IN 100's)			
	Opening Balance	Fresh issue	Other changes (give details)	Closing Balance
Equity shares with voting rights				
Year ended 31 March, 2022				
- Number of shares	125000	175000	-	300000
- Amount (F.V. of Rs.10 Each)	12500.00	17500.00	-	30000.00
Year ended 31 March, 2021				
- Number of shares	125000	-	-	125000
- Amount (F.V. of Rs.10 Each)	12500.00	-	-	12500.00

(ii) Details of shares held by each shareholder cum promoter:

Class of shares / Name of shareholder	As at 31 March, 2022		As at 31 March, 2021	
	Number of shares held	% holding in that class of shares	Number of shares held	% holding in that class of shares
<u>Equity shares with voting rights</u>				
1. Tejasbhai M. Hathi	45000	15.00%	18750	15.00%
2. Chatrabhuj V. Butani	45000	15.00%	18750	15.00%
3. Kapilbhai H. Chandarana	45000	15.00%	18750	15.00%
5. Riddhish Natwarlal Tanna	30000	10.00%	12500	10.00%
6. Gaurang Raneshbhai Thakkar	30000	10.00%	12500	10.00%
7. Milly Chetan Lalseta	30000	10.00%	12500	10.00%
8. Kripali Mayankbhai Thakkar	30000	10.00%	12500	10.00%
9. Kunjal Piyush Unadkat	30000	10.00%	12500	10.00%
10. Ghanshyambhai Pansuriya	15000	5.00%	6250	5.00%



M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

SUB NOTE TO NOTE "3"

(i) Details of terms of repayment for the other long-term borrowings and security provided in respect of the secured other long-term borrowings:

(I) Term Loans From Banks & Financial Institutions

Sr. No.	Particulars	Terms of repayment and security*	As at 31 March, 2022			As at 31 March, 2021		
			Total	Current	Net Balance	Total	Current	Net Balance
			(IN RS. 100)	(IN RS. 100)	(IN RS. 100)	(IN RS. 100)	(IN RS. 100)	(IN RS. 100)
Term loans from banks:								
1	ICICI Bank -Car Loan (Agreement No. 00037345129)	Car Ignis (Car Refinance Loan) (Payable in 60 EMI)	907.37	897.12	10.25	1680.05	772.68	907.37
2	Central Bank of India (Agreement No. 3812062248)	Cent Covid 19 Sahayata (Secured against current assets)	180.88	180.88	0.00	3624.95	2500.00	1124.95
3	Central Bank of India (Agreement No. 3832008015)	Cent GECL (Secured against current assets)	3841.98	1980.00	1861.98	5318.77	1950.00	3368.77
"A"			4930.23	3058	1872.23	10623.77	5222.68	5401.09
Term loans from banks (unsecured):								
1	HDFC Bank (Agreement No. 112654739)	Unsecured (Payable in 36 EMI)	16406.05	5792.92	10613.13	12969.24	4579.36	8389.88
"B"			16406.05	5792.92	10613.13	12969.24	4579.36	8389.88
Term loans from financial institutions (unsecured)								
1	Digikredit Finance Pvt. Ltd. (Agreement No. LANRAJ01UUBL000019184)	Unsecured (Payable in 36 EMI)	7594.96	4486.93	3108.03	19526.58	11931.62	7594.96
2	Bajaj Finance Ltd. (Agreement No. 416BLPGF671615)	Unsecured (Payable in 36 EMI)	9136.98	5823.41	3313.57	14031.47	4894.49	9136.98
"C"			16731.94	10310.34	6421.60	33558.05	16826.11	16731.94
Total - Term loans from banks & financial institutions (A+B+C)			38068.22	19161.26	18906.96	57151.06	26628.15	30522.91

(II) Term loans from other parties:

Sr. No.	Particulars	Terms of repayment and security*	As at 31 March, 2022		As at 31 March, 2021		
			Secured	Unsecured	Secured	Unsecured	
			(IN RS. 100)	(IN RS. 100)	(IN RS. 100)	(IN RS. 100)	
A From Directors							
1	Mr. Tejasbhai M. Hathi	(Without predetermined terms of repayment and interest)	NIL	55756.53	NIL	12256.53	
2	Mr. Kapilbhai H. Chandarana		NIL	10663.40	NIL	10663.40	
3	Mr. Chatrabhujbhai V. Butani		NIL	3600.04	NIL	3600.04	
"A"			NIL	70019.97	NIL	26519.97	
B From Share holders & their relatives							
1	Gaurang Thakkar	(Repayable in 3 Years)	NIL	3550.00	NIL	3550.00	
2	Kripal M. Thakkar		NIL	3550.00	NIL	3550.00	
3	Kunjai Anadkat		NIL	3550.00	NIL	3550.00	
4	Milly C. Lalseta		NIL	3550.00	NIL	3550.00	
5	Riddhish Tanna		NIL	3550.00	NIL	3550.00	
"B"			NIL	17750.00	NIL	17750.00	
Total - Term loans from other parties			NIL	87769.97	NIL	44269.97	



M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

SUB NOTES FORMING PARTS OF THE NOTES TO THE BALANCE SHEET AS AT 31.03.2022

**SUB NOTE TO NOTE "4"
SHORT TERM BORROWINGS**

(i) Details of security for the secured short-term borrowings:

SR. NO.	Particulars	Nature of security	As at 31st March, 2022		As at 31st March, 2021	
			Secured	Unsecured	Secured	Unsecured
			Amt. in Rs. 100	Amt. in Rs. 100	Amt. in Rs. 100	Amt. in Rs. 100
1	Loan Repayable on Demand From Banks: Central Bank of India (OD A/c No. 3498339851)	Stock & Book Debts	NIL	NIL	31845.07	NIL
Total - from banks			0	NIL	31845.07	NIL

**SUB NOTE TO NOTE " 5 "
ACCEPTANCES**

TRADE PAYABLES DUE FOR PAYMENT

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	-	-	-	-	-
(ii) Others	0	0	0	0	0
1 Accreation Nutraveda Pvt. Ltd.	2782.98	-	-	-	-
2 Accreation Pharmaceuticals	14194.78	-	-	-	-
3 Antila Lifesciences Pvt. Ltd.	0	112.83	-	-	-
4 Dizan Pharma	5.29	-	-	-	-
5 Erva Healthcare Pvt. Ltd.	2827.09	-	-	-	-
6 Hiral Labs Ltd.	796.34	-	-	-	-
7 Jyot Pharma	4.8	-	-	-	-
8 Logos Pharma	22226.72	-	-	-	-
9 Malik Lifesciences Pvt. Ltd.	10645.6	-	-	-	-
10 Merril Pharma Pvt. Ltd.	869.52	-	-	-	-
11 Pharma Co Healthcare	0	92.57	-	-	-
12 Pure & Cure Healthcare Pvt. Ltd.	4905.77	-	-	-	-
13 Shri Hari Pharmaceuticals	27897.68	-	-	-	-
14 Sotac Healthcare Pvt. Ltd.	1032.5	-	-	-	-
15 Weldew Remedies	1745.66	-	-	-	-
16 Zeon Biotech Pvt. Ltd.	888.25	-	-	-	-
17 Mexon Surgical	9.14	-	-	-	-
18 Western Surgical Rajkot	23.52	6.49	-	-	-
(iii) Disputed Dues - MSME	-	-	-	-	-
(iv) Disputed Dues - others	-	-	-	-	-
TOTAL	90855.64	211.89	0.00	0.00	0.00

